1. Abigerges D, Armand JP, Chabot GG, Cote C, Rougier P, Concalves E, Fadel E, Herait P, Gandia D (1993) High dose intensity of CPT-11 administered as a single dose every 3 weeks: the Institut Gustave Roussy experience. Proc Am Soc Clin Oncol 12:133
2. Bissery MC, Nguyen CH, Bisagni E, Lavelle F (1990) Preclinical evaluation of RP 60475, a pyrido-benzo-indole antitumor agent. Proc Am Assoc Cancer Res 31:2747
3. Burris HA III, Hanauske A-R, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD (1992) Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84:1816
4. Burris H, Kuhn J, Wall J, Eckardt J, Rodriguez G, Johnson R, Weiss G, Shaffer D, Von Hoff D (1992) Early clinical trials of topotecan, a new topoisomerase I inhibitor. Ann Oncol 3 [Suppl 1]:118
5. Chen S-F, Rothenberg ML, Clark G, Degen D, Wajima M, Barton D, Von Hoff DD (1994) Human tumor carboxylesterase activity correlates with CPT-11 cytotoxicity in vitro. Proc Am Assoc Cancer Res 35:2174